Anindya Bhattacharya
Vice President, Head of Neuroscience Switch Therapeutics
Anindya is a neuropharmacologist, an experienced drug hunter and has multiple years of R&D experience in Neuroscience. He joined Switch Therapeutics as Head of Neuroscience in 2023; prior to Switch, Anindya was the Global Head of Neuroimmunology at Janssen (Johnson & Johnson) where he championed the science of neuroinflammation and microglial biology. Anindya spent his entire career prosecuting druggable targets, moving projects from discovery to early development; he enjoys collaborative teamwork, project mentorship and leadership responsibilities. Anindya has led multiple project teams in chronic pain, neurodegeneration and neuropsychiatry, spanning different target classes and modalities. Anindya earned his Ph.D. in Pharmacology from SUNY, Buffalo and spent his postdoctoral training at Eli Lilly & Company. Anindya is an elected Fellow to the American College of Neuropsychopharmacology (ACNP) and has authored multiple primary manuscripts, book chapters and conference presentations.
Seminars
- Outlining the design principles of switchable oligo platforms, including triple-stranded siRNA architectures that enable RNAi activity to be modulated or restricted based on cellular context
- Showcasing pipeline applications in neurodegenerative disease, including programs targeting APOE and C1q, to illustrate how cell-selective RNAi can be aligned with disease-relevant biology, and sparing target mediated AEs
